Novo Nordisk’s new ‘king’ tightens his grip at obesity drug giant
Boardroom shake-up at European drugmaker grants Lars Rebien Sørensen wide-ranging powers
Related reading
Novo Nordisk loses further ground in obesity market
Danish drugmaker expects sales and profit growth at lower end of its guidance this year
Novo Nordisk calls for US import ban on key ingredient for obesity drug copycats
Danish group loses share in diabetes drugs to rivals, with first-half sales growth easing to 8%
Triple dose of Novo Nordisk drug delivers 19% weight loss in trials
Danish pharma group seeks to broaden options and stay competitive with Eli Lilly
Novo Nordisk faces more gloom from price cuts in crowded anti-obesity drugs…
Danish group’s challenges mount despite winning reprieve after Hims & Hers withdraws plan to sell copycat Wegovy pill
Novo Nordisk weight-loss drug wins US approval as a daily pill
Shares in Danish company rise as drugmaker secures lead in oral obesity treatment
Novo Nordisk chair and six board members to step down
Moves follow disagreement with Danish drugmaker’s majority shareholder the Novo Nordisk Foundation